Novacyt (LON:NCYT) Sets New 12-Month High – Here’s Why

Novacyt S.A. (LON:NCYT) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as GBX 81.40 and last traded at GBX 77.40, with a volume of 3538650 shares trading hands. The stock had previously closed at GBX 46.70.

Novacyt Stock Performance

The company has a current ratio of 4.74, a quick ratio of 4.46 and a debt-to-equity ratio of 44.73. The company’s 50-day simple moving average is GBX 34.85 and its 200-day simple moving average is GBX 36.09. The stock has a market capitalization of £39.13 million, a price-to-earnings ratio of -1.26 and a beta of 0.97.

Novacyt (LON:NCYT) last announced its quarterly earnings results on Thursday, April 30th. The company reported GBX (33) earnings per share (EPS) for the quarter. Novacyt had a negative net margin of 135.96% and a negative return on equity of 111.34%. The business had revenue of GBX 2,003 million during the quarter.

About Novacyt

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.